Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $16.8 million.

  • Silence Therapeutics' Total Current Liabilities rose 179.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 179.09%. This contributed to the annual value of $16.8 million for FY2024, which is 24.69% down from last year.
  • Per Silence Therapeutics' latest filing, its Total Current Liabilities stood at $16.8 million for FY2024, which was down 24.69% from $22.3 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Total Current Liabilities peaked at $32.8 million during FY2020, and registered a low of $16.8 million during FY2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $22.3 million (2023), whereas its average is $22.1 million.
  • In the last 5 years, Silence Therapeutics' Total Current Liabilities spiked by 166.46% in 2020 and then crashed by 36.46% in 2021.
  • Yearly analysis of 5 years shows Silence Therapeutics' Total Current Liabilities stood at $32.8 million in 2020, then plummeted by 36.46% to $20.9 million in 2021, then surged by 30.14% to $27.2 million in 2022, then fell by 17.75% to $22.3 million in 2023, then decreased by 24.69% to $16.8 million in 2024.